+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Type, By Product, By Site, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 6041028

Neuroendocrine Tumor Treatment Market Growth & Trends

The global neuroendocrine tumor treatment market size is expected to reach USD 3.73 billion by 2030. The market is estimated to register a CAGR of 6.0% from 2025 to 2030. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

Neuroendocrine Tumor Treatment Market Report Highlights

  • The carcinoid tumors segment dominated the market with a revenue share of 24.3% in 2024, driven by the increasing prevalence of carcinoid tumors and advancements in treatment methodologies.
  • The Somatostatin Analogs (SSAs) segment dominated the market with the largest revenue share in 2024, attributed to their proven efficacy in managing symptoms associated with neuroendocrine tumors.
  • The small intestine segment dominated the market with the largest revenue share in 2024, attributed to the higher incidence rates of neuroendocrine tumors originating from this site.
  • The hospitals segment dominated the market with the largest revenue share in 2024, driven by the comprehensive care offered by hospitals for complex cases of neuroendocrine tumors.
  • North America neuroendocrine tumor treatment market dominated the global market with a revenue share of 42.1% in 2024, driven by high healthcare expenditure coupled with advanced medical infrastructure.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Product
1.2.3. Site
1.2.4. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Neuroendocrine Tumor Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Neuroendocrine Tumor Treatment Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
4.4. Meningiomas
4.4.1. Meningiomas Market, 2018 - 2030 (USD Billion)
4.5. Adrenal Cancer
4.5.1. Adrenal Cancer Market, 2018 - 2030 (USD Billion)
4.6. Carcinoid Tumors
4.6.1. Carcinoid Tumors Market, 2018 - 2030 (USD Billion)
4.7. Paraganglioma
4.7.1. Paraganglioma Market, 2018 - 2030 (USD Billion)
4.8. Pheochromocytoma
4.8.1. Pheochromocytoma Market, 2018 - 2030 (USD Billion)
4.9. Others
4.9.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 5. Neuroendocrine Tumor Treatment Market: Product Business Analysis
5.1. Product Market Share, 2024 & 2030
5.2. Product Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
5.4. Somatostatin Analogs (SSAs)
5.4.1. Somatostatin Analogs (SSAs)Market, 2018 - 2030 (USD Billion)
5.5. Targeted Therapy
5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
5.6. Others
5.6.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. Neuroendocrine Tumor Treatment Market: Site Business Analysis
6.1. Site Market Share, 2024 & 2030
6.2. Site Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Site, 2018 to 2030 (USD Billion)
6.4. Lung
6.4.1. Lung Market, 2018 - 2030 (USD Billion)
6.5. Pancreas
6.5.1. Pancreas Market, 2018 - 2030 (USD Billion)
6.6. Colon
6.6.1. Colon Market, 2018 - 2030 (USD Billion)
6.7. Small Intestine
6.7.1. Small Intestine Market, 2018 - 2030 (USD Billion)
6.8. Rectum
6.8.1. Rectum Market, 2018 - 2030 (USD Billion)
6.9. Stomach
6.9.1. Stomach Market, 2018 - 2030 (USD Billion)
6.10. Others
6.10.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 7. Neuroendocrine Tumor Treatment Market: End Use Business Analysis
7.1. End Use Market Share, 2024 & 2030
7.2. End Use Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
7.4. Hospitals
7.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
7.5. Clinics
7.5.1. Clinics Market, 2018 - 2030 (USD Billion)
7.6. Others
7.6.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 8. Neuroendocrine Tumor Treatment Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5. Europe
8.5.1. Europe Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
8.6. Asia Pacific
8.6.1. Asia Pacific Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.7. Singapore
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Singapore Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.7. Latin America
8.7.1. Latin America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.8. MEA
8.8.1. MEA Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Novartis AG
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Type Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Bristol-Myers Squibb Company
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Type Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Pfizer Inc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Type Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Boehringer Ingelheim International GmbH
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Type Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Hutchison MediPharma Limited.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Type Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. AVEO Pharmaceuticals, Inc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Type Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Ipsen Pharma.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Type Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Eli Lilly and Company.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Type Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Exelixis, Inc.
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Type Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Jubilant Pharmova Limited
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Type Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global neuroendocrine tumor treatment market, by region, 2018 - 2030 (USD Billion)
Table 4 Global neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 5 Global neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 6 Global neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 7 Global neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 8 North America neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
Table 9 North America neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 10 North America neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 11 North America neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 12 North America neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 13 U.S. neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 14 U.S. neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 15 U.S. neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 16 U.S. neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 17 Canada neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 18 Canada neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 19 Canada neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 20 Canada neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 21 Mexico neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 22 Mexico neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 23 Mexico neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 24 Mexico neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 25 Europe neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
Table 26 Europe neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 27 Europe neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 28 Europe neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 29 Europe neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 30 UK neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 31 UK neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 32 UK neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 33 UK neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 34 Germany neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 35 Germany neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 36 Germany neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 37 Germany neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 38 France neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 39 France neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 40 France neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 41 France neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 42 Italy neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 43 Italy neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 44 Italy neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 45 Italy neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 46 Spain neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 47 Spain neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 48 Spain neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 49 Spain neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 50 Norway neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 51 Norway neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 52 Norway neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 53 Norway neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 54 Denmark neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 55 Denmark neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 56 Denmark neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 57 Denmark neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 58 Sweden neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 59 Sweden neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 60 Sweden neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 61 Sweden neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 62 Asia Pacific neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
Table 63 Asia Pacific neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 64 Asia Pacific neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 65 Asia Pacific neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 66 Asia Pacific neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 67 Japan neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 68 Japan neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 69 Japan neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 70 Japan neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 71 China neuroendocrine tumor treatment market, by type, 2018-2030 (USD Billion)
Table 72 China neuroendocrine tumor treatment market, by product, 2018-2030 (USD Billion)
Table 73 China neuroendocrine tumor treatment market, by site, 2018-2030 (USD Billion)
Table 74 China neuroendocrine tumor treatment market, by end use, 2018-2030 (USD Billion)
Table 75 India neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 76 India neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 77 India neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 78 India neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 79 Australia neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 80 Australia neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 81 Australia neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 82 Australia neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 83 South Korea neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 84 South Korea neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 85 South Korea neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 86 South Korea neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 87 Singapore neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 88 Singapore neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 89 Singapore neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 90 Singapore neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 91 Latin America neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
Table 92 Latin America neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 93 Latin America neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion
Table 94 Latin America neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion
Table 95 Latin America neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion
Table 96 Brazil neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 97 Brazil neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 98 Brazil neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 99 Brazil neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 100 Argentina neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 101 Argentina neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 102 Argentina neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 103 Argentina neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 104 Middle East & Africa neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
Table 105 Middle East & Africa neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 106 Middle East & Africa neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 107 Middle East & Africa neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 108 Middle East & Africa neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 109 South Africa neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 110 South Africa neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 111 South Africa neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 112 South Africa neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 113 Saudi Arabia neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 114 Saudi Arabia neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 115 Saudi Arabia neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 116 Saudi Arabia neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 117 UAE neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 118 UAE neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 119 UAE neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 120 UAE neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
Table 121 Kuwait neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
Table 122 Kuwait neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
Table 123 Kuwait neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
Table 124 Kuwait neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Neuroendocrine tumor treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Type outlook (USD Billion)
Fig. 10 Product outlook (USD Billion)
Fig. 11 Site outlook (USD Billion)
Fig. 12 End Use outlook (USD Billion)
Fig. 13 Competitive landscape
Fig. 14 Neuroendocrine tumor treatment market dynamics
Fig. 15 Neuroendocrine tumor treatment market: Porter’s five forces analysis
Fig. 16 Neuroendocrine tumor treatment market: PESTLE analysis
Fig. 17 Neuroendocrine tumor treatment market: Type segment dashboard
Fig. 18 Neuroendocrine tumor treatment market: Type market share analysis, 2024 & 2030
Fig. 19 Meningiomas market, 2018 - 2030 (USD Billion)
Fig. 20 Adrenal Cancer market, 2018 - 2030 (USD Billion)
Fig. 21 Carcinoid Tumors market, 2018 - 2030 (USD Billion)
Fig. 22 Paraganglioma market, 2018 - 2030 (USD Billion)
Fig. 23 Pheochromocytoma market, 2018 - 2030 (USD Billion)
Fig. 24 Others market, 2018 - 2030 (USD Billion)
Fig. 25 Neuroendocrine tumor treatment market: Product segment dashboard
Fig. 26 Neuroendocrine tumor treatment market: Product market share analysis, 2024 & 2030
Fig. 27 Somatostatin analogs (SSAs) market, 2018 - 2030 (USD Billion)
Fig. 28 Targeted therapy market, 2018 - 2030 (USD Billion)
Fig. 29 Others market, 2018 - 2030 (USD Billion)
Fig. 30 Neuroendocrine tumor treatment market: Site segment dashboard
Fig. 31 Neuroendocrine tumor treatment market: Site market share analysis, 2024 & 2030
Fig. 32 Lung market, 2018 - 2030 (USD Billion)
Fig. 33 Pancreas market, 2018 - 2030 (USD Billion)
Fig. 34 Colon market, 2018 - 2030 (USD Billion)
Fig. 35 Small Intestine market, 2018 - 2030 (USD Billion)
Fig. 36 Rectum market, 2018 - 2030 (USD Billion)
Fig. 37 Stomach market, 2018 - 2030 (USD Billion)
Fig. 38 Others market, 2018 - 2030 (USD Billion)
Fig. 39 Neuroendocrine tumor treatment market revenue, by region
Fig. 40 Regional marketplace: Key takeaways
Fig. 41 North America neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 42 U.S. country dynamics
Fig. 43 U.S. neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 44 Canada country dynamics
Fig. 45 Canada neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 46 Mexico country dynamics
Fig. 47 Mexico neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 48 Europe neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 49 UK country dynamics
Fig. 50 UK neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 51 Germany country dynamics
Fig. 52 Germany neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 53 France country dynamics
Fig. 54 France neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 55 Italy country dynamics
Fig. 56 Italy neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 57 Spain country dynamics
Fig. 58 Spain neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 59 Norway country dynamics
Fig. 60 Norway neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 61 Denmark country dynamics
Fig. 62 Denmark neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion
Fig. 63 Sweden country dynamics
Fig. 64 Sweden neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 65 Asia Pacific neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 66 Japan country dynamics
Fig. 67 Japan neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 68 China country dynamics
Fig. 69 China neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 70 India country dynamics
Fig. 71 India neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 72 South Korea country dynamics
Fig. 73 South Korea neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 74 Australia country dynamics
Fig. 75 Australia neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 76 Singapore country dynamics
Fig. 77 Singapore neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 78 Latin America neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 79 Brazil country dynamics
Fig. 80 Brazil neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 81 Argentina country dynamics
Fig. 82 Argentina neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 83 MEA neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 84 South Africa country dynamics
Fig. 85 South Africa neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 86 Saudi Arabia country dynamics
Fig. 87 Saudi Arabia neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 88 UAE country dynamics
Fig. 89 UAE neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 90 Kuwait country dynamics
Fig. 91 Kuwait neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
Fig. 92 Company categorization
Fig. 93 Company market position analysis
Fig. 94 Strategic framework

Companies Mentioned

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Hutchison MediPharma Limited.
  • AVEO Pharmaceuticals, Inc.
  • Ipsen Pharma.
  • Eli Lilly and Company.
  • Exelixis, Inc.
  • Jubilant Pharmova Limited

Methodology

Loading
LOADING...

Table Information